About SynthegoSynthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
For more information, visit www.synthego.com and follow us on www:twitter.com/synthego
Founder: Michael Dabrowski and Alex Pesch
CEO: Paul Dabrowski
Please click here for Synthego job opportunities.
Tweets by Synthego
24 articles with Synthego
Novel bioinformatics-powered multi-guide design guarantees gene knockouts in any human-derived cell type, eliminating trial-and-error in CRISPR guide design
Synthego Launches $1 Million in Grants to Foster Innovation and Accelerate Discovery in Genome Engineering Research
Grants further Synthego's mission of providing the next generation of Genome Engineers access to CRISPR tools to enable novel research
Eurofins will distribute Synthego's synthetic single guide RNA to their global customer database across 44 countries.
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
10/23/2018Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.
Series C investment expedites Synthego's CRISPR product expansion to facilitate industry development of new therapies, adds cell therapy pioneer Dr. Matthew Porteus to advisory board
Synthego Launches Engineered Cells Product Portfolio as Next Step in Delivering Genome Engineering Access to All Scientists
Engineered Cells single-click ordering and knockout guarantee removes barriers to world-class CRISPR results
Synthego Appoints CRISPR Pioneer Dr. Jennifer Doudna to Advisory Board to Accelerate Company's Genome Engineering Mission
Doudna to advise Synthego as the company develops technology and services to further the adoption of CRISPR, bringing access, precision and automation to genome engineering
Here is a look at the life science companies viewed as the most innovative in the world.
Synthego, a leading provider of genome engineering solutions, announces an investment from Intel Capital for the advancement of bioinformatics tools and technologies. This represents Intel Capital's first financing in bioinformatics related to the CRISPR workflow.
Synthego And Thermo Fisher Scientific Align To Manufacture And Distribute Synthetic Guide RNA Products For CRISPR Genome Engineering
Synthego Announces World's First Modified Synthetic sgRNA Libraries For Arrayed Whole Genome CRISPR Screening
Synthego Awards Synthetic sgRNA Grant To University of Oxford For CRISPR Research Applications In The UK
Synthego Announces Modified Synthetic sgRNA -- Critical For Editing Primary And Stem Cells, And Other Challenging Cell Types
Synthego Release: Survey: Over 80 Percent Of New CRISPR Users Are Conducting Gene Editing For The First Time
Synthego's 12 Days Of CRISPR Educates Scientists On CRISPR Genome Editing, Offers Grants Totaling $100,000 Of Synthetic RNA